---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020831"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:05:12.106326+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical Q1 net loss $9.3M; Phase 2b ODYSSEY trial to open Q2 2023

## Summary
- Net loss of $9.3M ($0.15 per share) vs $7.6M ($0.13) in Q1 2022.
- Cash and equivalents $41.4M; company expects to fund operations into Q2 2024.
- R&D expenses flat at $4.5M; G&A down to $3.2M from $3.5M.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD to open enrollment Q2 2023; topline results expected Q3 2024.
- Positive safety and duration data from OASIS Phase 1/2a extension study presented at ARVO.

## SEC filing metadata
- accession: 0000950170-23-020831
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/0000950170-23-020831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/clsd-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020831
- JSON: https://secwatch.observer/filing/0000950170-23-020831.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020831.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported the first quarter ended March 31, 2023 results: revenue $4,000, net income $9.3 million, EPS $0.15 per share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $4,000
  - Net income: $9.3 million
  - EPS: $0.15 per share
  - Result: reported results
  source text: First Quarter 2023 Financial Results • License Revenue: Clearside’s license and other revenue for the first quarter of 2023 was $4,000, compared to $347,000 for the first quarter of 2022. • Research and Development (R&D) Expenses : R&D expenses for the first quarter of 2023 and the first quarter of 2002 were $4.5 million. • General and Administrative (G&A) Expenses : G&A expenses for the first quarter of 2023 were $3.2 million, compared to $3.5 million for the first quarter of 2022. • Other Income: Other income for the first quarter of 2023 was $492,000, compared to $2,000 for the first quarter of 2022. Other income in both periods was comprised of interest income from cash and cash equivalents. • Other Expense : Non-cash interest expense for the first quarter of 2023 was $2.2 million, compared to $0 in the first quarter of 2022. Non-cash interest expense was comprised of imputed interest on the liability related to the sales of future royalties and the amortization of the associated i
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/0000950170-23-020831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.